- Quarterly Report (10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________

FORM 10-Q

_________________________

(Mark One)

x	Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2009

¨	Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File No. 001-32569

_________________________

AMERICAN ORIENTAL BIOENGINEERING, INC.

(Exact Name of Registrant as Specified in Its Charter)

_________________________

NEVADA	84-0605867
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1 Liangshuihe First Ave, Beijing E-Town Economic and Technology Development Area, E-Town,

Beijing, 100176, People’s Republic of China

(Address of principal executive offices) (Zip Code)

86-10-5982-2039

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

_________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	¨	Accelerated filer	x
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of each class the issuer’s common stock as of the latest practicable date is stated below


Title of each class of common stock		Outstanding as of June 30, 2009
Preferred Stock, $0.001 par value		1,000,000
Common Stock, $0.001 par value		78,301,439

Table of Contents


PART I – FINANCIAL INFORMATION	3

ITEM 1 – FINANCIAL STATEMENTS	3

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	21

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	30

ITEM 4 – CONTROLS AND PROCEDURES	30

PART II – OTHER INFORMATION	31

ITEM 1 – LEGAL PROCEEDINGS	31

ITEM 1A – RISK FACTORS	31

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	31

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES	31

ITEM 4 – SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS	31

ITEM 5 – OTHER INFORMATION	31

ITEM 6 – EXHIBITS	31

PART I – FINANCIAL INFORMATION

ITEM 1 – FINANCIAL STATEMENTS

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS

	JUNE 30, 2009		DECEMBER 31, 2008
	(UNAUDITED)
CURRENT ASSETS
Cash and cash equivalents	$	100,730,402	$	70,636,510
Accounts receivable, net of reserve of $505,433 and $226,330
at June 30, 2009 and December 31, 2008, respectively		31,396,881		36,982,167
Inventories, net		16,829,834		13,042,123
Advances to suppliers		3,135,694		3,593,979
Notes receivable		81,075		708,076
Refundable deposit		-		6,396,996
Deferred tax assets		421,660		347,216
Other current assets		937,087		744,903
Total Current Assets		153,532,633		132,451,970

LONG-TERM ASSETS
Property, plant and equipment, net		96,151,689		98,154,443
Land use rights, net		148,301,203		148,988,870
Deposit for long-term assets		6,717,514		6,347,174
Construction in progress		25,871,656		25,385,835
Deferred tax assets		1,327,627		1,313,832
Other intangible assets, net		21,146,928		23,690,440
Goodwill		28,543,226		28,543,226
Long-term investment and advance		55,452,267		54,963,064
Unamortized financing cost		3,751,838		4,215,983
Total Long-Term Assets		387,263,948		391,602,867

TOTAL ASSETS	$	540,796,581	$	524,054,837

See accompanying notes to the condensed consolidated financial statements

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

LIABILITIES AND EQUITY

	JUNE 30, 2009			DECEMBER 31, 2008
	(UNAUDITED)
CURRENT LIABILITIES
Accounts payable	$	12,548,451		$	12,287,887
Notes payables		3,011,486			3,262,877
Other payables and accrued expenses		14,251,673			19,766,652
Taxes payable		625,261			420,671
Short-term bank loans		6,720,430			7,140,148
Current portion of long-term bank loans		59,396			58,659
Other liabilities		2,511,295			2,253,440
Deferred tax liability		1,121,738			846,026
Total Current Liabilities		40,849,730			46,036,360

LONG-TERM LIABILITIES
Long-term bank loans, net of current portion		774,641			804,521
Long-term notes payable		-			269,908
Deferred tax liabilities		15,963,766			16,083,768
Convertible notes		115,000,000			115,000,000
Total Long-Term Liabilities		131,738,407			132,158,197
TOTAL LIABILITIES		172,588,137			178,194,557

COMMITMENTS

EQUITY
SHAREHOLDERS’ EQUITY
Preferred stock, $0.001 par value; 2,000,000 shares authorized;
1,000,000 shares issued and outstanding at June 30, 2009 and December 31, 2008, respectively		1,000			1,000
Common stock, $0.001 par value; 150,000,000 shares authorized;
78,301,439 and 78,249,264 shares issued and outstanding at June 30, 2009 and December 31, 2008, respectively.		78,301			78,249
Common stock to be issued		311,999			376,335
Prepaid forward repurchase contract		(29,998,616	)		(29,998,616	)
Additional paid-in capital		196,752,860			195,741,544
Retained earnings (the restricted portion of retained earnings is $29,532,699
at June 30, 2009 and December 31, 2008, respectively)		171,019,548			149,923,681
Accumulated other comprehensive income		29,510,788			29,086,006
Total Shareholders’ Equity		367,675,880			345,208,199
NON-CONTROLLING INTEREST		532,564			652,081
TOTAL EQUITY		368,208,444			345,860,280
TOTAL LIABILITIES AND EQUITY	$	540,796,581		$	524,054,837

See accompanying notes to the condensed consolidated financial statements

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(UNAUDITED)

	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2009			2008			2009			2008

REVENUES	$	71,222,037		$	59,010,005		$	117,299,227		$	97,778,603
COST OF GOODS SOLD		29,594,923			18,928,447			47,255,261			31,406,083
GROSS PROFIT		41,627,114			40,081,558			70,043,966			66,372,520

Selling and marketing		9,396,129			7,687,892			14,607,631			12,717,600
Advertising		7,779,936			7,452,231			13,347,293			11,846,572
General and administrative		4,315,714			5,253,274			8,881,357			9,165,957
Depreciation and amortization		1,850,274			1,010,461			3,709,189			1,987,671
Total operating expenses		23,342,053			21,403,858			40,545,470			35,717,800

INCOME FROM OPERATIONS		18,285,061			18,677,700			29,498,496			30,654,720

EQUITY IN EARNINGS (LOSS) FROM UNCONSOLIDATED ENTITIES		(173,258	)		(640,008	)		264,536			(641,067	)
INTEREST INCOME (EXPENSE), NET		(1,620,069	)		(30,616	)		(3,199,338	)		(13,769	)
OTHER INCOME (EXPENSE), NET		(16,329	)		(255,770	)		(114,938	)		(356,502	)
INCOME BEFORE INCOME TAXES		16,475,405			17,751,306			26,448,756			29,643,382

INCOME TAXES		3,369,107			3,891,614			5,472,406			6,361,562

NET INCOME		13,106,298			13,859,692			20,976,350			23,281,820
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST		123,068			-			119,517			-
NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST		13,229,366			13,859,692			21,095,867			23,281,820

OTHER COMPREHENSIVE INCOME
Foreign currency translation gain, net of tax		46,316			5,154,761			424,782			12,089,196
TOTAL OTHER COMPREHENSIVE INCOME, NET OF TAX		46,316			5,154,761			424,782			12,089,196

COMPREHENSIVE INCOME	$	13,275,682		$	19,014,453		$	21,520,649		$	35,371,016

NET INCOME PER SHARE
BASIC	$	0.18		$	0.18		$	0.28		$	0.30
DILUTED	$	0.17		$	0.18		$	0.28		$	0.30

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
BASIC		74,582,920			78,223,659			74,560,809			78,207,405
DILUTED		88,815,593			78,223,659			86,939,711			78,208,181

See accompanying notes to the condensed consolidated financial statements

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(UNAUDITED)

	Six Months Ended June 30,
	2009		2008

CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	20,976,350	$	23,281,820
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		6,445,556		4,641,379
Amortization of financing cost		464,145		-
Amortization of deferred consulting expenses		-		104,500
Provision for (reversal of) doubtful accounts		278,602		(140,250)
Changes in provision for slow moving inventories		53,605		(175,627)
Deferred taxes		67,471		714,100
Common stock to be issued for services		80,000		68,000
Stock option compensation expense		673,035		374,019
Independent director stock compensation		194,000		182,333
Loss on disposal of assets		4,745		(7,657)
Equity in (income) loss from unconsolidated entities		(264,536)		641,101

Changes in operating assets and liabilities:
(Increase) Decrease In:
Accounts receivable		5,307,187		(697,207)
Notes receivable		627,001		1,567,744
Inventories		(3,841,052)		(6,538,693)
Advances to suppliers and prepaid expenses		458,285		1,324,457
Other current asset		(192,184)		1,208,187

Increase (Decrease) In:
Accounts payable		260,564		1,235,110
Other payables and accrued expenses		(5,514,977)		495,796
Taxes payable		204,590		922,717
Other liabilities		257,855		(827,080)
Net cash provided by operating activities		26,540,242		28,374,749

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of construction in progress		(535,881)		(223,742)
Purchases of property, plant and equipment		(149,837)		(391,877)
Purchase of land use right		(757,187)		-
Purchases of other intangible assets		-		(95,900)
Refundable deposit		6,396,996		(2,888,960)
Deposit for long-term assets		(361,375)		(34,852,986)
Proceeds from disposal of plant and equipment		620		-
Investments in and advances to equity investments		(172,812)		(19,657,535)
Net cash used in investing activities		4,420,524		(58,111,000)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from bank loans		4,817,870		3,524,627
Repayments of bank loans		(5,276,275)		(3,551,083)
Repayment of capital lease		-		(10,011)
Proceeds from notes payable		4,363,367		-
Deferred financing costs		-		(290,000)
Repayment of notes payable		(4,889,392)		(61,951)
Net cash used in financing activities		(984,430)		(388,418)

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		29,976,336		(30,124,669)
Effect of exchange rate changes on cash		117,556		8,187,869
Cash and cash equivalents, beginning of year		70,636,510		166,410,075

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	100,730,402	$	144,473,275

See accompanying notes to the condensed consolidated financial statements

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

NOTE 1 – BASIS OF PRESENTATION

The unaudited condensed consolidated financial statements of American Oriental Bioengineering, Inc. and subsidiaries (the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the requirements for reporting on Form 10-Q. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. However, the information included in these interim financial statements reflects all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for the fair presentation of the consolidated financial position and the consolidated results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full year. The condensed consolidated balance sheet information as of December 31, 2008 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K. These interim financial statements should be read in conjunction with that report.

Basis of Consolidation - The condensed consolidated financial statements include the accounts of American Oriental Bioengineering, Inc. and its wholly owned subsidiaries. The Company’s subsidiaries are included in the consolidated financial statements. Inter-company accounts and transactions have been eliminated in consolidation.

Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Management makes these estimates using the best information available at the time the estimates are made; however, actual results when ultimately realized could differ from those estimates. See “Critical Accounting Policies and Estimates” in the Management’s Discussion and Analysis of Financial Condition and Results of Operations” section below.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS

Revenue Recognition – Revenues represent the invoiced value of goods sold, recognized upon the shipment of goods to customers. Revenues are recognized when all of the following criteria are met:

●

Persuasive evidence of an arrangement exists,

●

Delivery has occurred or services have been rendered,

●

The seller's price to the buyer is fixed or determinable, and

●

Collectability is reasonably assured.

Selling and Marketing Expenses – Selling and marketing expenses include the costs of selling merchandise, including preparing the merchandise for sale, such as picking, packing, warehousing and order charges. All shipping and handling are expensed as incurred and outbound freight is not billed to customers.

Advertising Costs – The Company expenses advertising costs as incurred or the first time advertising takes place. Point of sale materials are accounted for as inventory and charged to expense as utilized.

Research and Development – Research and development costs are expensed as incurred. Engineers and technical staff are involved in the production of our products as well as on-going research, with no segregation of the portion of their salaries relating to research and development from the portion of their salaries relating to production. The total salaries are included in cost of goods sold. Research and development expense for the three months ended June 30, 2009 and 2008 is $354,651 and $272,977, respectively and is included in general and administrative expenses.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

Foreign Currency Translation – The accompanying condensed consolidated financial statements are presented in United States dollars (USD). The functional currency of the Company is the Chinese Renminbi (RMB). Capital accounts of the condensed consolidated financial statements are translated into United States dollars from RMB at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rates as of balance sheet date. Income and expenditures are translated at the average exchange rate for the quarter.

	2009	2008
Quarter end RMB : US$ exchange rate	6.8448	6.8718
Average quarterly RMB : US$ exchange rate	6.8452	6.9470

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.

Comprehensive Income – Comprehensive income is defined to include changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, items that are required to be recognized under current accounting standards as components of comprehensive income are required to be reported in a financial statement that is presented with the same prominence as other financial statements. Comprehensive income includes net income and the foreign currency translation gain, net of tax.

Stock Based Compensation – The Company estimates fair value of restricted stock based on the number of shares granted and the quoted price of the Company’s common stock on the date of grant. The fair value of stock options is estimated using the Black-Scholes model. The Company’s expected volatility assumption is based on the historical volatility of Company’s stock. The expected life assumption is primarily based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

Stock compensation expense recognized is based on awards expected to vest, and there were no estimated forfeitures as the current options outstanding were only issued to founders and senior executives of the Company, which have very low turnover. SFAS No. 123R requires forfeitures to be estimated at the time of grant and revised in subsequent periods, if necessary, if actual forfeitures differ from those estimates.

The fair value of the stock based compensation expense for the three and six months ended June 30, 2009 was $535,404 and $867,035, respectively.

Income Taxes – The Company accounts for income tax using an asset and liability approach and allows for recognition of deferred tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before either the Company is able to realize their benefits, or that future realization is uncertain. The Company had adopted FIN 48 January 1, 2007. See Note 18.

Segment Reporting – The Company has two operating segments based on its major lines of businesses: manufacturing and distribution. Each operating segment derives its revenues from the sale of products or services, respectively and each is the responsibility of a group of senior management of the Company who has knowledge of product and service specific operational risks and opportunities. The Company’s chief operating decision maker reviews and evaluates two sets of financial information deciding how to allocate resources and in assessing performance.

For the three and six months ended June 30, 2009 and 2008 the Company’s manufacturing and distribution revenue are as follows:

	Three Months Ended June 30, (Unaudited)				Six Months Ended June 30, (Unaudited)
	2009		2008		2009		2008
Revenue from pharmaceutical products	$	58,438,805	$	49,792,442	$	93,118,274	$	81,651,824
Revenue from nutraceutical products		9,523,090		9,217,563		18,435,483		16,126,779
Total manufacturing revenue		67,961,895		59,010,005		111,553,757		97,778,603
Distribution revenue		3,260,142		-		5,745,470		-

Total revenue	$	71,222,037	$	59,010,005	$	117,299,227	$	97,778,603

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

For the three and six months ended June 30, 2009 and 2008 the Company’s operating income are as follows:

	Three Months Ended June 30, (Unaudited)					Six Months Ended June 30, (Unaudited)
	2009			2008		2009			2008
Operating income from pharmaceutical products	$	15,047,340		$	14,882,775	$	22,810,346		$	24,114,990
Operating income from nutraceutical products		3,660,073			3,794,925		7,100,972			6,539,730
Total manufacturing operating income		18,707,413			18,677,700		29,911,318			30,654,720
Distribution operating income		(422,352	)		-		(412,822	)		-

Total operating income	$	18,285,061		$	18,677,700	$	29,498,496		$	30,654,720

At June 30, 2009 and December 31, 2008, the total assets for the manufacturing, distribution and corporate segments are as follows:

	June 30, 2009		December 31, 2008
	(Unaudited)
Manufacturing	$	341,538,501	$	312,146,154
Distribution		51,880,830		52,445,008
Corporate		147,377,250		159,463,675

Total assets	$	540,796,581	$	524,054,837

Cash and Cash Equivalents – The Company considers all highly liquid investments purchased with original maturities of six months or less to be cash equivalents. The majority of the Company’s cash as of June 30, 2009 is in our current working capital bank account. Included in the cash balance as of June 30, 2009 was $2,619,574 restricted cash for the issuance of bank acceptance notes.

Fair Value of Financial Instruments – SFAS 157 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1—defined as observable inputs such as quoted prices in active markets;

Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The assets measured at fair value on a recurring basis subject to the disclosure requirements of SFAS 157 as of June 30, 2009 are as follows:

		Fair Value Measurements at Reporting Date Using
	Carrying value as of June 30, 2009	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$100,730,402	$100,730,402	-	-

Cash and cash equivalents consist primarily of highly rated money market funds at a variety of well-known institutions with original maturities of three months or less. The original cost of these assets approximates fair value due to their short term maturity.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

Recently Issued Accounting Standards

On April 1, 2009, the FASB approved FSP FAS 141(R)-1, Accounting for Assets Acquired and Liabilities Assumed in a Business Combination That Arise from Contingencies, which amends Statement 141(R) and eliminates the distinction between contractual and non-contractual contingencies. Under FSP FAS 141(R), an acquirer is required to recognize at fair value an asset acquired or liability assumed in a business combination that arises from a contingency if the acquisition-date fair value of that asset or liability can be determined during the measurement period. If the acquisition-date fair value cannot be determined, the acquirer applies the recognition criteria in SFAS No. 5, Accounting for Contingencies and Interpretation 14, “Reasonable Estimation of the Amount of a Loss – and interpretation of FASB Statement No. 5,” to determine whether the contingency should be recognized as of the acquisition date or after it. We are currently evaluating the potential impact of adopting this statement.

FSP FAS 115-2 and FAS 124-2 amend the other-than-temporary impairment guidance in U.S. GAAP for debt securities to make the guidance more operational and to improve the presentation and disclosure of other-than-temporary impairments on debt and equity securities in the financial statements. It did not amend existing recognition and measurement guidance related to other-than-temporary impairments of equity securities. We are required to adopt this FSP for our interim and annual reporting periods ending after June 15, 2009. This FSP does not require disclosures for periods presented for comparative purposes at initial adoption. This FSP requires comparative disclosures only for periods ending after initial adoption. We are currently evaluating the potential impact of adopting this statement.

On April 9, 2009, the FASB also approved FSP FAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments to require disclosures about fair value of financial instruments in interim period financial statements of publicly traded companies and in summarized financial information required by APB Opinion No. 28, Interim Financial Reporting . We are required to adopt this FSP for our interim and annual reporting periods ending after June 15, 2009. This FSP does not require disclosures for periods presented for comparative purposes at initial adoption. This FSP requires comparative disclosures only for periods ending after initial adoption. We are currently evaluating the potential impact of adopting this statement.

NOTE 3 – EARNINGS PER SHARE

Basic earnings per share are computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding, excluding common shares to be delivered under a prepaid forward repurchase contract (3,712,700 shares), during the period. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

The following is a reconciliation of the numerator and denominator used in the calculation of basic and diluted earnings per share available to common shareholders.

	Three Months Ended June 30, (Unaudited)				Six Months Ended June 30, (Unaudited)
	2009		2008		2009		2008

Numerator:
Net income attributable to controlling interest	$	13,229,366	$	13,859,692	$	21,095,867	$	23,281,820
Interest expense on convertible securities, net of taxes		1,437,500		-		2,875,000		-
Amortization of financing costs, net of taxes		232,072		-		464,145		-
Net income, as adjusted	$	14,898,938	$	13,859,692	$	24,435,012	$	23,281,820

Denominator:
Weighted average shares outstanding – Basic		74,582,920		78,223,659		74,560,809		78,207,405
Effect of dilutive instruments:
Convertible notes		14,232,673		-		12,378,902		-
Warrants				-				776
Weighted average shares outstanding - Diluted		88,815,593		78,223,659		86,939,711		78,208,181

The calculation of weighted average common shares outstanding for the diluted calculation excludes consideration of stock options for the three and six months ended June 30, 2009 and 2008, respectively, because the exercise of these options would not have been dilutive for those periods due to the fact that the exercise prices were greater than the weighted average market price of our common stock for each of those periods.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

As more fully discussed in Notes 14, the Company had certain convertible notes outstanding during the periods presented. The aggregate number of shares of common stock that could be issued in the future to settle these notes is deemed outstanding for the purposes of the calculation of diluted earnings per share. This approach, referred to as the if-converted method, requires that such shares be deemed outstanding regardless of whether the notes are then contractually convertible into the Company’s common stock. For this if-converted calculation, the interest expense and issuance costs (net of tax) attributable to these notes are added back to Net Income, reflecting the assumption that the notes have been converted.

NOTE 4 – INVENTORIES

Inventories are summarized as follows:

	June 30, 2009			December 31, 2008
	(Unaudited)
Raw materials	$	5,853,906		$	5,569,981
Work in progress		3,575,441			2,350,291
Finished goods		7,621,784			5,289,280
		17,051,131			13,209,552
Less: provision for slow moving inventories		(221,297	)		(167,429	)
Inventories, net	$	16,829,834		$	13,042,123

NOTE 5 – NOTES RECEIVABLE

Notes receivable are bank acceptance notes collected from customers. The notes do not bear interest and are to be received within one year.

NOTE 6 – LAND USE RIGHTS

Land use rights consist of the following:

	June 30, 2009		December 31, 2008
	(Unaudited)
Cost of land use rights	$	153,185,732	$	152,297,695
Less: Accumulated amortization		(4,884,529)		(3,308,825	)
Land use rights, net	$	148,301,203	$	148,988,870

Amortization expense for the three months ended June 30, 2009 and 2008 was $786,235 and $276,143, respectively. Amortization expense for the six months ended June 30, 2009 and 2008 was $1,570,865 and $543,766, respectively.

As of June 30, 2009, the net book value of land use rights pledged as collateral was $13,390,881. See Note 13.

NOTE 7 – CONSTRUCTION IN PROGRESS

Construction in progress as of June 30, 2009 and December 31, 2008 was $25,871,656 and $25,385,835, respectively. During 2008, the Company acquired land use rights located close to its operating subsidiaries and started construction projects for the expansion of manufacturing facilities. These construction projects were in progress as of June 30, 2009.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

NOTE 8 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consist of the following:

	June 30, 2009			December 31, 2008
	(Unaudited)
At cost:
Buildings	$	91,319,664		$	91,261,579
Machinery and equipment		20,839,094			20,665,315
Motor vehicles		1,568,875			1,568,059
Office equipment		1,619,985			1,543,300
Other equipment		482,682			482,097
Leasehold improvement		29,190			29,150
		115,859,490			115,549,500
Less : Accumulated depreciation
Buildings		(5,892,719	)		(4,732,906	)
Machinery and equipment		(11,658,463	)		(10,782,285	)
Motor vehicles		(1,107,398	)		(998,535	)
Office equipment		(900,090	)		(771,630	)
Other equipment		(127,238	)		(91,078	)
Leasehold improvement		(21,893	)		(18,623	)
		(19,707,801	)		(17,395,057	)
Property, plant and equipment, net	$	96,151,689		$	98,154,443

Depreciation expense for the three months ended June 30, 2009 and 2008 was $1,141,903 and $808,138, respectively. Depreciation expense for the six months ended June 30, 2009 and 2008 was $ 2,299,681 and $1,590,158, respectively.

As of June 30, 2009, the net book value of property, plant and equipment pledged as collateral for bank loans was $4,285,607. See Note 13.

NOTE 9 – OTHER INTANGIBLE ASSETS, NET

Other intangible assets are summarized as follows:

	June 30, 2009			December 31, 2008
	(Unaudited)
At cost:
Product licenses	$	15,507,205			15,485,939
Trademarks		10,573,160			10,558,660
Patents		4,802,768			4,796,179
Proprietary technology		282,051			281,664
Software		73,740			73,640
		31,238,924			31,196,082
Less: Accumulated amortization		(10,091,996	)		(7,505,642	)
Other intangible assets, net	$	21,146,928			23,690,440

Amortization expense for the three months ended June 30, 2009 and 2008 was $1,282,010 and $1,273,624 respectively. Amortization expense for the six months ended June 30, 2009 and 2008 was $2,575,007 and $2,507,195 respectively.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

NOTE 10 –ACQUISITIONS

On October 18, 2008, the Company acquired from the Nuo Hua Investment Company Limited (“Nuo Hua”) shareholders all of the issued and outstanding shares of capital stock of Nuo Hua. Nuo Hua owns 55% equity of a pharmaceutical distribution company in Jilin province, and 30% equity of a wholesale and a distribution company in Shandong province, (“Nuo Hua Affiliate”). Nuo Hua, through its subsidiary and affiliated company, distributes pharmaceutical products through sales network covering major urban and rural areas in China.

On October 20, 2008, the Company acquired from the GuangXi HuiKe Pharmaceutical Research and Development Co., Ltd. (“GHK”) shareholders all of the issued and outstanding shares of capital stock of GHK. GHK is engaged in pharmaceutical research and product development leading to SFDA approval and expedient product launches in China. The Company provides research and development through innovative technology, raw material selection, extraction and production of pharmaceutical products.

The results of operations for Nuo Hua and GHK are included in the consolidated results of operations for the six months ended June 30, 2009.

The following unaudited pro forma combined condensed statements of income for the six months ended June 30, 2008 have been prepared as if the acquisitions of Nuo Hua and GHK occurred on January 1, 2008. The statements are based on accounting for the business acquisitions under purchase accounting. The pro forma information may not be indicative of the results that actually would have occurred if the acquisition had been in effect from and on the dates indicated or which may be obtained in the future.

	Six Months Ended June 30,
	2008 Pro Forma Combined
Revenues	$	142,966,318
Income from Operations		30,655,809
Net Income attribute to controlling interest		23,462,078
Net Income Per Share
Basic	$	0.30
Diluted	$	0.30
Weighted Average number of shares outstanding
Basic		78,207,405
Diluted		78,208,181

NOTE 11 – INVESTMENTS AND ADVANCES IN UNCONSOLIDATED ENTITIES

Long-term investments and advances include our equity investment in China Aoxing Pharmaceutical Company, Inc. (“CAXG”), equity investments in a wholesale and distribution company in Shandong province, (“Nuo Hua Affiliate”) and Hezhou Jinji Color Printing Co Ltd. (“Jinji Printing”). CAXG is a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products in China. Nuo Hua Affiliate maintains a significant presence in pharmaceutical wholesale and retail distribution in China. Jinji Printing is a color printing company focusing on the printing of external packaging materials.

The Company owns 36% equity interest in CAXG through an $18 million direct investment of its common stock in April 2008. The cost of investment in excess of our estimate of the underlying equity in net assets at the time of the investments was estimated to be around $1,369,799. The Company also owns 30% equity interest in Nuo Hua Affiliate through the acquisition of Nuo Hua Investment Company Ltd. in October 2008 and the Company owns 40% equity interest in Jinji Printing through the acquisition of Guangxi Lingfeng Pharmaceutical Co. in April 2006. Long-term investments are accounted for using the equity accounting method.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

The following table summarizes the long-term investments and advances as of June 30, 2009 and December 31, 2008:

	June 30, 2009			December 31, 2008
	(Unaudited)
Cost of investments:
CAXG	$	18,000,000		$	18,000,000
Nuo Hua Affiliate		32,999,023			32,999,023
Jinji Printing printing		86,067			86,067
Share of equity income (loss):
CAXG		(2,413,141	)		(1,580,344	)
Nuo Hua Affiliate		1,916,070			773,415
Jinji Printing		43,940			42,303
Advances:
CAXG		4,702,130			4,520,209
Jinji Printing		118,178			122,391

Long-term investment and advances	$	55,452,267		$	54,963,064

For the three and six months ended June 30, 2009 the Company’s equity in earnings from unconsolidated entities are as follows:

	Three Months Ended June 30, 2009 (Unaudited)			Six Months Ended June 30, 2009 (Unaudited)
Equity in income from Nuo Hua Affiliate	$	601,970		$	1,095,873
Equity in loss from CAXG		(775,272	)		(832,797	)
Equity in income from Jinji Printing		44			1,460
Total equity in earnings (loss) from unconsolidated entities	$	(173,258	)	$	264,536

Included in the advance to CAXG is a RMB30 million, or approximately $4.3 million, convertible promissory note principal the accrued interest. The note bears interest at a rate of 8% payable quarterly in arrears with an initial term of one year and was subsequently extended for an additional three months. The note will be due on August 26, 2009. CAXG may elect to make the quarterly loan payments in cash or to convert the payments into shares of its common stock. The Company also has the option to receive payment in shares of CAXG’s common stock if CAXG is either unable to repay the loan in cash or consents to the conversion of its payment obligations into shares of its common stock.

NOTE 12 – DEPOSIT FOR LONG-TERM ASSETS

Deposits for long term assets are refundable deposits to acquire land use rights located in the PRC. The long-lived assets to be acquired will be for use in the expansion of some of the Company's current manufacturing facilities and are not intended for resale by the Company. The deposits will be reclassified to the respective accounts under the long lived assets upon the transfers of legal title.

NOTE 13 – DEBT

Short-term bank loans are obtained from local banks with interest rate from 5.31% to 7.47% per annum. All the short-term bank loans are repayable within one year and are secured by plant and equipment and land use rights owned by the Company. See Notes 6 and 8.

Long-term loan includes a mortgage loan that bears 4.25% interest per annum and is repayable over 15 years.

Current notes payable was $3,011,486 as of June 30, 2009 with interest rate at 5.29% per annum and is repayable on demand.

Interest expense for all outstanding debt was $346,022 and $200,503 for the three months ended June 30, 2009 and 2008, respectively. Interest expense for all outstanding debt was $693,078 and $393,741 for the six months ended June 30, 2009 and 2008, respectively

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

NOTE 14 – CONVERTIBLE NOTES AND PREPAID FORWARD CONTRACT

On July 15, 2008, the Company closed a private offering and issued $115 million aggregate principal amount of 5.00% Convertible Senior Notes due 2015 (the “Notes”). The Notes were sold to qualified institutional buyers in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended. The net proceeds from the sale of the Notes was approximately $110 million, after deducting the placement agents’ commission and estimated offering expenses payable by the Company. The following is a brief summary of certain terms of this offering.

Total offering is $115,000,000 aggregate principal amount of 5.00% Convertible Senior Notes due on July 15, 2015.

Interest at 5.00% per year, payable semiannually in arrears in cash.

The Notes are convertible, at the option of the holder, at any time prior to the close of business on the second business day preceding the maturity date based on an initial conversion rate of 107.6195 shares per $1,000 principal amount of Notes, which represents an initial conversion price of approximately $9.29 per share.

The conversion rate is subject to certain adjustments. In particular, holders who convert their Notes in connection with certain fundamental changes may be entitled to a make whole premium in the form of additional shares of our common stock.

Holders may require the Company to purchase all or a portion of their Notes on July 15, 2013 for cash at a price equal to 100% of the principal amount of the Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the purchase date.

If a fundamental change occurs, holders will have the right to require the Company to purchase for cash all or any portion of their Notes. The fundamental change purchase price will be 100% of the principal amount of the Notes to be purchased plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date.

The Notes will be direct unsecured, unsubordinated obligations and will rank equal in right of payment to all of the Company’s existing and future unsecured and unsubordinated indebtedness. The Notes will be effectively subordinated to all of the Company’s existing and future secured indebtedness.

Convertible notes issuance costs incurred by the Company that were directly attributable to the issuance of the Notes were deferred and are charged to the consolidated statements of income using the straight-line method over the term of the convertible notes, the results of which approximate the effective interest rate method.

The Company has determined that the conversion feature embedded in the Notes is not required to be bifurcated and accounted for as a derivative pursuant to SFAS No. 133 “Accounting for Derivative Instruments and Hedging Activities”, since the embedded conversion feature is indexed to the Company’s own stock, after considering EITF 07-5, “Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock”, and would be classified in shareholders’ equity if it was a free-standing instrument pursuant to guidance in EITF 00-19, “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock”. Further, since the conversion price of the Notes exceeded the market price of the Company’s ordinary shares on the date of issuance of the Notes, no portion of the proceeds from the issuance was accounted for as attributable to the conversion feature.

As of June 30, 2009, the conversion price was set at $8.08 per share.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

NOTE 15 – PREPAID FORWARD SHARES REPURCHASE TRANSACTION

In connection with the offering of the Notes, the Company entered into a prepaid forward shares repurchase contract with an affiliate of the lead placement agent (“Merrill affiliate”). Pursuant to the prepaid forward shares repurchase contract, the Company paid approximately $30 million to the Merrill affiliate to fund the purchase of 3.7 million shares of common stock for settlement at or about maturity of the notes. The forward shares purchase transaction was also intended to reduce the potential dilution of our common stock that would result from the conversion of the Notes into shares of our common stock.

The Company accounted for the forward shares purchase transaction pursuant to guidance in EITF 00-19. Accordingly, the $30 million cost of the forward stock purchase transaction was recorded as a reduction to additional paid in capital in the Balance Sheet and will not recognize subsequent changes in fair value.

The Company is potentially subject to significant concentration of credit risk with respect to the prepaid forward repurchase contract. The fact that the Merrill affiliate has merged with Bank of America reduced the bankruptcy and default risk. We will closely monitor the third depositary and may request early settlement of the contract prior to the maturity of the convertible notes.

NOTE 16 – SHAREHOLDERS’ EQUITY

Preferred Stock

The Company has 1,000,000 shares of Series A preferred stock (“Series A”) issued and outstanding. Pursuant to the terms of the Series A, the holder holds aggregate voting power equal to 25% of the combined voting power of our common stock and preferred stock. The percentage of voting power represented by the Series A cannot be diluted by the issuance of additional shares of common stock. The Series A has a liquidation preference equal to its initial issue price that will be paid to the holders of the Series A upon liquidation, dissolution or winding up and prior to any distributions being made to holders of our common stock.

Common Stock

A. Issuance of Common Stock

During the six months ended June 30, 2009, the Company issued 42,471 restricted common stocks as stock compensation in connection with the services rendered by the Company’s independent directors in 2008. The Company also issued 9,704 shares of common stock to a consultant as partial payment of consulting fee.

B. Stock Options

The Company recorded total stock option compensation expenses of $320,405 and $555,036 for the three and six months ended June 30, 2009. Of the total value of the option grants, $4,226,072 has not yet been recognized and will be amortized over the requisite service periods.

The following table summarizes the stock option activities of the Company:


	Activity		Weighted Average Exercise Price
Outstanding as of January 1, 2009		2,421,257	$	8.58
Granted		1,027,100		4.01
Exercised		-		—
Cancelled		-		—

Outstanding as of June 30, 2009		3,448,357	$	7.22

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

The following table summarizes information about stock options outstanding as of June 30, 2009:

	Options Outstanding						Options Exercisable
Range of Exercise Prices	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Number of Shares		Weighted Average Exercise Price
$ 8.54 - $10.74		969,500	$	10.04		3		325,900	$	10.32
$ 4.95 - $8.35		1,451,757	$	7.62		4		227,451	$	8.35
$ 0.87		1,027,100	$	4.01		5		-
		3,448,357						553,351

Options granted have no intrinsic value at grant date and at the date of these financial statements as the exercise price of all vested or unvested options was higher than the market price. The weighted average fair value per share of the 3,448,357 options issued under the Company’s 2006 Equity Incentive Plan is $1.72 per share. As of June 30, 2009, the Company has 553,351 outstanding vested stock options, with an exercise price above the average market price, which are excluded from the Company’s diluted computation.

C. Common Stock to be Issued

For the three and six months ended June 30, 2009, the Company recorded general and administrative expenses of $69,831 for the stock compensation in connection with the services rendered by the Company’s executives and $48,168 for the senior management.

For the three and six months ended June 30, 2009, the Company recorded general and administrative expenses of $97,000 and $194,000, respectively, for the stock compensation in connection with the services rendered by the Company’s independent directors and $40,200 and $120,200, respectively, for a consultant.

A total of 62,405 shares of common stock are issuable as of June 30, 2009.

NOTE 17 – COMMITMENTS

As of June 30, 2009, the Company had entered into unconditional capital commitments for the purchases of construction in progress manufacturing facilities in the People’s Republic of China for $5,903,930 within one year and $13,585,715 after one year. In addition, the Company had advertisement contract commitments for $4,959,483.

As of June 30, 2009, the Company has $1,429,053 material unconditional purchase commitments for raw materials within one year and $0 after one year.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

NOTE 18 – TAXES

(a) Corporate Income Tax (“CIT”)

The Company has not recorded a provision for U.S. federal income tax for the quarter ended June 30, 2009 due to the net operating loss carry forward in the United States.

On March 16, 2007, the National People’s Congress of China approved the new Corporate Income Tax Law of the People’s Republic of China (the “New CIT Law”), which is effective from January 1, 2008. Under the new CIT Law, the corporate income tax rate applicable to most companies is 25% instead of the old tax rate of 33%. The new CIT Law also provides certain tax concession to selective eligible companies. All our manufacturing subsidiaries, including GLP, Boke, Three Happiness, HSPL and CCXA were granted high-tech enterprise status and enjoy a favorable tax rate of 15% from 2008 to 2010. High-tech enterprise status is renewable and re-application should be done prior to the tax preferences expire. HQPL, Nuo Hua and GHK do not qualify for any tax concession and they have a 25% tax rate.

The Company’s tax expense differs from the “expected” tax expense as follows:

	Three Months Ended June 30, (Unaudited)						Six Months Ended June 30, (Unaudited)
	2009			2008			2009			2008
Computed "expected" expense	$	5,357,620		$	5,265,036		$	7,850,070		$	8,636,155
Favorable tax rate effect		(2,143,027	)		(1,389,576	)		(3,533,330	)		(2,258,254	)
Permanent difference		154,514			16,154			1,155,666			(16,339	)
Income tax expense	$	3,369,107		$	3,891,614		$	5,472,406		$	6,361,562

The provisions for income taxes are summarized as follows:

	Three Months Ended June 30, (Unaudited)					Six Months Ended June 30 , (Unaudited)
	2009			2008		2009			2008
Current	$	3,478,167		$	3,866,137	$	5,660,450		$	6,415,276
Deferred		(109,060	)		25,477		(188,044	)		(53,714	)
Total	$	3,369,107		$	3,891,614	$	5,472,406		$	6,361,562

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

The tax effects of temporary differences that give rise to the Company’s net deferred tax liabilities as of June 30, 2009 and December 31, 2008 are as follows:

	June 30, 2009			December 31, 2008
	(Unaudited)
Deferred tax assets
Current
Bad debts	$	102,720		$	9,651
Other costs		318,940			337,565
Total current deferred tax assets		421,660			347,216
Non-current
Bad debts		216,391			216,094
Amortization		176,529			164,313
Other costs		859,815			858,636
Stock provision		32,128			32,083
Depreciation		42,764			42,706
Total non-current deferred tax assets		1,327,627			1,313,832
Total deferred tax assets	$	1,749,287		$	1,661,048
Deferred tax liabilities
Current
Over accrual of welfare	$	(114,997	)	$	(114,840	)
Boke acquisition		(943,828	)		(667,096	)
CCXA acquisition		5,943			45,704
Other		(68,856	)		(109,794	)
Total current deferred tax liabilities		(1,121,738	)		(846,026	)
Non-current
Over accrual of welfare		(18,308	)		(18,283	)
Amortization		(325,743	)		(291,034	)
Depreciation		(180,526	)		(130,803	)
Government grant		(948,492	)		(1,019,319	)
GLP acquisition		(3,836,552	)		(3,831,290	)
CCXA acquisition		(4,396,103	)		(4,429,843	)
Boke acquisition		(2,714,259	)		(2,985,975	)
Others		(238,806	)		(166,351	)
Other comprehensive income		(3,304,977	)		(3,210,870	)
Total non-current deferred tax liabilities		(15,963,766	)		(16,083,768	)
Total deferred tax liabilities		(17,085,504	)		(16,929,794	)
Net deferred tax liabilities	$	(15,336,217	)	$	(15,268,746	)

The Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Interpretation No. 48, “Accounting for Uncertainty in Income Taxes - an Interpretation of FASB Statement No. 109,” (“FIN 48”), on January 1, 2007. The Company did not have any material unrecognized tax benefits and there was no effect on its financial condition or results of operations as a result of implementing FIN 48.

(b) Value Added Tax (“VAT”)

Enterprises or individuals who sell commodities, engage in repair and maintenance or import or export goods in the PRC are subject to a value added tax in accordance with the PRC laws. The value added tax standard rate is 17% of the gross sales price. A credit is available whereby VAT paid on the purchases of semi-finished products or raw materials used in the production of the Company’s finished products can be used to offset the VAT due on the sales of the finished products.

The VAT payable balance of $4,023,109 and $6,262,715 at June 30, 2009 and December 31, 2008 respectively are included in Other Payables and Accrued Expenses in the accompanying condensed consolidated balance sheets.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2009

(UNAUDITED)

Income before income tax expense was $26.45 million and $29.64 million for the six months ended June 30, 2009 and 2008 and was mainly attributed to subsidiaries with operations in China. Income tax related to China income for the six months ended June 30, 2009 was $5.47 million. The combined unaudited pro forma effects of the income tax expense exemptions and reductions available to us are as follows:

	Six Months Ended June 30, (Unaudited)
	2009		2008
Tax holiday effect	$	3,533,330	$	2,258,254
Basic net income per share excluding tax holiday effect	$	0.24	$	0.27

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the information contained in the condensed consolidated financial statements of the Company and the notes thereto appearing elsewhere herein and in conjunction with the Management’s Discussion and Analysis set forth in (1) the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, and (2) the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. Readers should carefully review the risk factors disclosed in the Company’s Form 10-K for the year ended December 31, 2008 filed by the Company with the Securities and Exchange Commission (SEC)..

As used in this report, the terms “Company”, “we”, “our”, “us” and “AOB” refer to American Oriental Bioengineering, Inc., a Nevada corporation.

PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as “anticipate,” “expect,” “intend,” “plan,” “will,” “we believe,” “AOB believes,” “management believes” and similar language. The forward-looking statements are based on the current expectations of AOB and are subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this report. Actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assume no obligation to update them.

Investors are also advised to refer to the information in our previous filings with the SEC, especially on Forms 10-K, 10-Q and 8-K, in which we discuss in more detail various important factors that could cause actual results to differ from expected or historic results. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks and uncertainties or potentially inaccurate assumptions.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

This section should be read together with the Summary of Significant Accounting Policies included as Note 2 to the consolidated financial statements included in our Annual Report on Form 10-K for 2008 filed with the SEC.

Estimates affecting accounts receivable and inventories

The preparation of our consolidated financial statements requires management to make estimates and assumptions that affect our reporting of assets and liabilities (and contingent assets and liabilities). These estimates are particularly significant where they affect the reported net realizable value of the Company’s accounts receivable and inventories.

At June 30, 2009, the Company provided a $505,433 reserve against accounts receivable. Management’s estimate of the appropriate reserve on accounts receivable at June 30, 2009 was based on the aged nature of these accounts receivable. In making its judgment, management assessed its customers’ ability to continue to pay their outstanding invoices on a timely basis, and whether their financial position might deteriorate significantly in the future, which would result in their inability to pay their debts to the Company.

At June 30, 2009, the Company provided an allowance against its inventories amounting to $221,297. Management determination of this allowance is based on potential impairments to the current carrying value of the inventories due to slow moving of aged inventories. In making its estimate, management considered the probable demand for our products in the future and historical trends in the turnover of our inventories.

While the Company currently believes that there is little likelihood that actual results will differ materially from these current estimates, if customer demand for our products decreases significantly in the near future, or if the financial condition of our customers deteriorates in the near future, the Company could realize significant write downs for slow-moving inventories or uncollectible accounts receivable.

Policy affecting recognition of revenue

Among the most important accounting policies affecting our consolidated financial statements is our policy of recognizing revenue in accordance with the SEC’s Staff Accounting Bulletin (“SAB”) No. 104. Under this policy, all of the following criteria must be met in order for us to recognize revenue:

1. Persuasive evidence of an arrangement exists;

2. Delivery has occurred or services have been rendered;

3. The seller’s price to the buyer is fixed or determinable; and

4. Collectability is reasonably assured.

The majority of the Company’s revenue results from sales contracts with distributors and revenue is recorded upon the shipment of goods. Management conducts credit background checks for new customers as a means to reduce the subjectivity of assuring collectability. Based on these factors, the Company believes that it can apply the provisions of SAB 104 with minimal subjectivity.

RECENT ACCOUNTING PRONOUNCEMENT

A description of recent accounting pronouncements is set forth under “New Accounting Standards” in Note 2 of the Notes to the Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q, and such description is incorporated herein by reference. Such description contains all of the information required with respect thereto.

RESULTS OF OPERATIONS – THREE MONTHS ENDED JUNE 30, 2009 AS COMPARED TO THREE MONTHS ENDED JUNE 30, 2008

The following table sets forth the amounts and the percentage relationship to revenues of certain items in our condensed consolidated statements of income for the three months ended June 30, 2009 and 2008:

	Three Months Ended June 30,						Three Months Ended June 30,
	2009			2008			2009			2008
REVENUES	$	71,222,037		$	59,010,005			100	%		100	%
COST OF GOODS SOLD		29,594,923			18,928,447			41. 6			32.1
GROSS PROFIT		41,627,114			40,081,558			58.4			67.9
Selling and marketing		9,396,129			7,687,892			13.2			13.0
Advertising		7,779,936			7,452,231			10.9			12.6
General and administrative		4,315,714			5,253,274			6.1			8.9
Depreciation and amortization		1,850,274			1,010,461			2.6			1.7
Total operating expenses		23,342,053			21,403,858			32.8			36.2
INCOME FROM OPERATIONS		18,285,061			18,677,700			25.6			31.7
Equity in earnings from unconsolidated entities		(173,258	)		(640,008	)		(0.2	)		(1.1	)
Interest income (expense), net		(1,620,069	)		(30,616	)		(2.3	)		(0.1	)
Other expense, net		(16,329	)		(255,770	)		(0.0	)		(0.4	)
INCOME BEFORE INCOME TAXES		16,475,405			17,751,306			23.1			30.1
Income taxes		3,369,107			3,891,614			4.7			6.6
NET INCOME		13,106,298			13,859,692			18.4			23.5
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST		123,068			-			0.2			-
NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST	$	13,229,366		$	13,859,692			18.6	%		23.5	%

Revenues

Revenues for the second quarter of 2009 were $71,222,037, an increase of $12,212,032 over revenues for the second quarter of 2008. We classify our revenues in two segments: Manufacturing revenue, which comprises sales by our subsidiaries of our pharmaceutical and nutraceutical products, and Distribution revenue. Revenues by segments and product categories were as follows:

	Three Months Ended June 30,				Increase/ (Decrease)		Increase/ (Decrease)
	2009		2008		Increase/ (Decrease)		Increase/ (Decrease)
Revenue from pharmaceutical products	$	58,438,805	$	49,792,442	$	8,646,363		17.4	.%
Revenue from nutraceutical products		9,523,090		9,217,563		305,527		3.3	%
Total manufacturing revenue		67,961,895		59,010,005		8,951,890		15.2	%
Distribution revenue		3,260,142		-		3,260,142		100	%
Total revenue	$	71,222,037	$	59,010,005	$	12,212,032		20.7	%

Sales of our pharmaceutical products increased by $ 8,646,363 , or 17.4%, as compared to the same period of 2008 primarily due to the following factors:

The sales of our prescription pharmaceutical products increased from $20,425,161 during the second quarter of 2008 to $25,163,884 in the same period of 2009, or a 23.2% increase. This is primarily due to the increase in sales of our prescription formulated Jinji capsule and CCXA prescription pharmaceutical products despite the decrease in sales of our SHL products. The overall increase in sales was supported by our continuous marketing efforts, increase in products offering, effective pricing strategy, as well as expanding coverage to the previously unaddressed rural market; and

·	The sales of our OTC pharmaceutical products increased from $29,367,281 to $33,274,921. This was attributable to the increase in sales of our Boke and GLP products as a result of improved recognition of our product supported by our marketing campaigns.

Sales from our nutraceutical products increased from $9,217,563 during the second quarter of 2008 to $9,523,090 in the same period of 2009, representing a growth of 3.3% Sales of our nutraceutical beverage series increased by 87.2% from $436,034 during the second quarter of 2008 to $816,366 during the second quarter of 2009. This increase was mainly attributed to new beverage producs launched in the beginning of 2009.

The Company has recorded $3,260,142 distribution revenue from Nuo Hua's majority owned subsidiary, during the three months ended June 30, 2009. Since the Company’s investment in Nuo Hua did not occur until October, 2008, the Company had no distribution revenue for the quarter ended June 30, 2008.

Cost of Goods Sold and Gross Profit

Cost of goods sold was $29,594,923 for the three months ended June 30, 2009, compared to $18,928,447 for the three months ended June 30, 2008.

	Three Months Ended June 30,
	2009		2008		Increase/ (Decrease)		Increase/ (Decrease)
Pharmaceutical products	$	22,576,349	$	15,307,572	$	7,268,777		47.5%
Nutraceutical products		3,871,851		3,620,875		250,976		6.9%
Total manufacturing cost		26,448,200		18,928,447		7,519,753		39.7%
Distribution cost		3,146,723		-		3,146,723		100%
Total cost	$	29,594,923	$	18,928,447	$	10,666,476		56.4%

The cost of goods sold of pharmaceutical and nutraceutical products increased by 47.5% and 6.9% in the three months ended June 30, 2009 compared to the three months ended June 30, 2008, respectively. These increases are attributed to our increase in sales. The Company had no distribution revenue and thus there was no corresponding cost of goods sold with respect to distribution services for the three months ended June 30, 2008.

Gross profit increased by $1,545,556, or 3.9%, for the three months ended June 30, 2009 over the three months ended June 30, 2008. This increase reflected higher net sales.

Gross profit as a percentage of net revenues decreased from 67.9% in the comparable period of the prior year to 58.4% in the second quarter of 2009 due to sales of more lower margin products by CCXA in the second quarter of 2009 compared to the same period of 2008. Further, the purchase prices of certain raw materials increased the cost of goods sold and lower margin distribution business from Nuo Hua also contributed to lower gross profit..

Selling and Marketing

Selling and marketing expenses, including distribution expenses, increased from $7,687,892 in the three months ended June 30, 2008 to $9,396,129 in the same period of 2009, representing an increase of 22.2%. The details of our selling and marketing expenses are as follows:

	Three Months Ended June 30,
	2009		2008		Increase/ (Decrease)			Increase/ (Decrease)
Promotional materials and fees	$	5,526,908	$	4,084,853	$	1,442,055			35.3		%
Payroll		1,338,517		1,395,716		(57,199	)		(4.1	)	%
Shipping		1,039,217		618,512		420,705			68.0		%
Traveling		647,184		501,722		145,462			29.0		%
Sales conference		581,019		610,511		(29,492	)		(4.8	)	%
Offices supplies		195,641		270,765		(75,124	)		(27.7	)	%
Other expenses		67,643		205,813		(138,170	)		(67.1	)	%
TOTAL	$	9,396,129	$	7,687,892	$	1,708,237			22.2		%

The increase in selling and marketing expenses in the quarter ended June 30, 2009 compared to the same quarter during 2008 was primarily due to the following factors:

·	Promotional materials and fees increased 35.3% from $4,084,853 to $5,526,908 during the second quarter of 2009 as compared to the same quarter of 2008. This was primarily due to the increase in our promotion activities and initiatives to support the continuous growth of our revenue.

·	Shipping increased 68% from $618,512 to $1,039,217 during the second quarter of 2009 as compared to the same quarter of 2008. This was primarily due to the increase of net sales.

Advertising

Advertising expenses increased by $327,705, from $7,452,231 in the second quarter of 2008 to $7,779,936 in the same quarter of 2009. The increase in advertising expense resulted from an increase in promotional efforts and media advertisement to promote the Company’s Jinji series, Boke Nose Spray and Protein Peptide series of products.

Advertising expenses as a percentage of revenue decreased slightly from 12.6% in the second quarter of 2008 to 10.9% in the same quarter of 2009.

General and Administrative

General and administrative expenses decreased from $5,253,274 in the second quarter of 2008 to $4,315,714 in the same quarter of 2009, or a 17.8% decrease. The details of general and administrative expenses were as follows:

	Three Months Ended June 30,
	2009		2008			Increase/ (Decrease)			Increase/ (Decrease)
Payroll	$	938,173	$	1,122,654		$	(184,481	)		(16.4	)%
Directors’ remuneration		661,141		756,313			(95,172	)		(12.6	)%
Professional fees - accounting		421,669		432,875			(11,206	)		(2.6	)%
Research and development		354,651		272,977			81,674			29.9	%
Staff welfare and insurance		311,198		496,508			(185,310	)		(37.3	)%
Provision for bad debts		372,294		(140,344	)		512,638			365.3	%
Trip and traveling		268,556		269,306			(750	)		(0.3	)%
Office supplies		172,863		183,792			(10,929	)		(5.9	)%
Vehicles and utilities		120,128		118,593			1,535			1.3	%
Stock compensation - management and consult		144,463		48,000			96,463			201.0	%
Professional fees – legal and consulting		104,065		796,558			(692,493	)		(86.9	)%
Investors relation and listing expenses		64,234		86,414			(22,180	)		(25.7	)%
Office rental		16,497		51,842			(35,345	)		(68.2	)%
Other expenses		365,782		757,786			(392,004	)		(51.7	)%
TOTAL	$	4,315,714	$	5,253,274		$	(937,560	)		(17.8	)%

The decrease in general and administrative expenses in the three months ended June 30, 2009 compared to the same period during 2008 was primarily due to the following factors:

Legal and consulting related professional fees decreased by $692,493, or 86.9% as compared to the same quarter during 2008. We incurred increased fees during the second quarter of 2008, due to fund raising activities undertaken during that time. We did not have any fund raising activities during the second quarter of 2009 ; and

·	Payroll expenses decreased by $184,481, or 16.4% and Staff welfare and insurance expenses decreased by $185,310, or 37.3% as compared to the same quarter during 2008. These reflect the Company’s increased efforts in optimization of human resource management and cost control; and

·	Research and development increased by $81,674, or 29.9%, as compared to the same period of 2008, due to our increased R&D effort on new products and existing products enhancement;

Depreciation and Amortization

Depreciation and amortization expenses increased by $839,813 or 83.1%, in the quarter ended June 30, 2009 compared to the same quarter during 2008. This increase was primarily due to the depreciation and amortization charges of the facilities and lands acquired during 2008.

Depreciation and amortization expense for the R&D facilities was $199,360 for the three months ended June 30, 2009.

Interest Income (Expense), Net

Net interest expense was $1,620,069 for the three months ended June 30, 2009, compared to net interest expense of $30,616 for the three months ended June 30, 2008. The increase was mainly related to the convertible notes issued in July 2008.

Other expense, Net

Other expense was $16,329 for the three months ended June 30, 2009 compared to $255,770 for the three months ended June 30, 2008. Other expense in the second quarter of 2008 was primarily due to our donation of $168,641 related to the Sichuan earthquake relief during the second quarter of 2008. There were no such donations during the second quarter of 2009.

Income Taxes

Income tax expense for the quarter ended June 30, 2009 was $3,369,107, compared to $3,891,614 for the quarter ended June 30, 2008. The Company’s effective tax rate for this quarter was 20.4%.

RESULTS OF OPERATIONS – SIX MONTHS ENDED JUNE 30, 2009 AS COMPARED TO SIX MONTHS ENDED JUNE 30, 2008

The following table sets forth the amounts and the percentage relationship to revenues of certain items in our condensed consolidated statements of income for the six months ended June 30, 2009 and 2008:

	Six Months Ended June 30,						Six Months Ended June 30,
	2009			2008			2009			2008
REVENUES	$	117,299,227		$	97,778,603			100	%		100	%
COST OF GOODS SOLD		47,255,261			31,406,083			40.3			32.1
GROSS PROFIT		70,043,966			66,372,520			59.7			67. 9
Selling and marketing		14,607,631			12,717,600			12.5			13.0
Advertising		13,347,293			11,846,572			11.3			12.1
General and administrative		8,881,357			9,165,957			7.6			9.4
Depreciation and amortization		3,709,189			1,987,671			3.1			2.0
Total operating expenses		40,545,470			35,717,800			34.5			36.5
INCOME FROM OPERATIONS		29,498,496			30,654,720			25.2			31.4
Equity in earnings from unconsolidated entities		264,536			(641,067	)		0.2			(0.7	)
Interest income (expense), net		(3,199,338	)		(13,769	)		(2.7	)		(0.0	)
Other expense, net		(114,938	)		(356,502	)		(0.1	)		(0.4	)
INCOME BEFORE INCOME TAXES		26,448,756			29,643,382			22.6			30.3
Income taxes		5,472,406			6,361,562			4.7			6.5
NET INCOME		20,976,350			23,281,820			17.9			23.8
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST		119,517			-			0.1			-
NET INCOME ATTRIBUTABLE TO CONTROLLING INTEREST	$	21,095,867		$	23,281,820			18.0	%		23.8	%

Revenues

Revenues for the six months ended June 30, 2009 were $117,299,227, an increase of $19,520,624 over revenues for the same period of 2008. We classify our revenues in two segments: Manufacturing revenue, which comprises sales by our subsidiaries of our pharmaceutical and nutraceutical products, and Distribution revenue. Revenues by segments and product categories were as follows:

	Six Months Ended June 30,				Increase/ (Decrease)		Increase/ (Decrease)
	2009		2008		Increase/ (Decrease)		Increase/ (Decrease)
Revenue from pharmaceutical products	$	93,118,274	$	81,651,824	$	11,466,450		14.0	%
Revenue from nutraceutical products		18,435,483		16,126,779		2,308,704		14.3	%
Total manufacturing revenue		111,553,757		97,778,603		13,775,154		14.1	%
Distribution revenue		5,745,470		-		5,745,470		100	%
Total revenue	$	117,299,227	$	97,778,603	$	19,520,624		20	%

Sales of our pharmaceutical products increased by $11,466,450, or 14%, as compared to the same period of 2008 primarily due to the following factors:

The sales of our prescription pharmaceutical products increased from $34,577,339 during the first six months of 2008 to $41,367,074 in the same period of 2009, or a 19.6% increase. This is primarily due to the increase in sales of our prescription formulated Jinji capsule and CCXA prescription pharmaceutical products despite the decrease in sales of our SHL products. The overall increase in sales was supported by our continuous marketing efforts, increase in products offering, effective pricing strategy, as well as expanding coverage to the previously unaddressed rural market; and

·	The sales of our OTC pharmaceutical products increased from $47,074,485 to $51,751,200, or a 9.9% increase. This was attributable to the increase in sales of our Boke products as a result of improved recognition of our product supported by our marketing campaigns.

Sales from our nutraceutical products increased from $16,126,779 during the six months ended June 30 of 2008 to $18,435,483 in the same period of 2009, representing a growth of 14.3% and it is primarily due to the following factors:

Sales of our Protein Peptide series of products increased by 9%, from $15,165,287 during the six months ended June 30 of 2008 to $16,526,267 in the same period of 2009. This increase was mainly attributed to the increase in sales of peptide coffee and peptide powder through our expanded distribution network; and

·	Sales of our nutraceutical beverage series increased by 126.1% from $834,804 during the six months ended June 30 of 2008 to $1,887,510 during the first quarter of 2009. This increase was mainly attributed to new beverage products launched during the six months ended June 30 of 2009.

The Company has recorded $5,745,470 distribution revenue from Nuo Hua's majority owned subsidiary, during the six months ended June 30, 2009. Since the Company’s investment in Nuo Hua did not occur until October, 2008, the Company had no distribution revenue for the first six months ended June 30, 2008.

Cost of Goods Sold and Gross Profit

Cost of goods sold was $47,255,261 for the six months ended June 30, 2009, compared to $31,406,083 for the six months ended June 30, 2008.

	Six Months Ended June 30,
	2009		2008		Increase/ (Decrease)		Increase/ (Decrease)
Pharmaceutical products	$	34,294,274	$	25,097,208	$	9,197,066		36.6%
Nutraceutical products		7,424,764		6,308,875		1,115,889		17.7%
Total manufacturing cost		41,719,038		31,406,083		10,312,955		32.8%
Distribution cost		5,536,223		-		5,536,223		100%
Total cost	$	47,255,261	$	31,406,083	$	15,849,178		50.5%

The cost of goods sold of pharmaceutical and nutraceutical products increased by 36.6% and 17.7%, respectively, in the six months ended June 30, 2009 compared to the same period of 2008. These increases are attributed to our increase in sales. The Company had no distribution revenue and thus there was no corresponding cost of goods sold with respect to distribution services for the six months ended June 30, 2008.

Gross profit increased by $3,671,446, or 5.5%, for the six months ended June 30, 2009 over the same period of 2008. This increase reflected higher net sales.

Gross profit as a percentage of net revenues decreased from 67.9% in the comparable period of the prior year to 59.7% in the six months ended June 30, 2009 due to sales of much lower margin products by CCXA in the six moths ended quarter June 30, 2009 compared to the same period of 2008. Further, the purchase prices of certain raw materials increased the cost of goods sold and lower margin distribution business from Nuo Hua also contributed to lower gross profit..

Selling and Marketing

Selling and marketing expenses, including distribution expenses, increased from $12,717,600 in the six months ended June 30, 2008 to $14,607,631 in the same period of 2009, representing an increase of 14.9%. The details of our selling and marketing expenses are as follows:

	Six Months Ended June 30,
	2009		2008		Increase/ (Decrease)			Increase/ (Decrease)
Promotional materials and fees	$	7,412,340	$	5,483,559	$	1,928,781			35.2	%
Payroll		2,724,892		2,808,937		(84,045	)		(3.0	)%
Shipping		1,854,302		1,464,589		389,713			26.6	%
Traveling		1,266,864		1,337,513		(70,649	)		(5.3	)%
Sales conference		840,942		787,214		53,728			6.8	%
Offices supplies		310,324		470,484		(160,160	)		(34.0	)%
Other expenses		197,967		365,304		(167,337	)		(45.8	)%
TOTAL	$	14,607,631	$	12,717,600	$	1,890,031			14.9	%

The increase in selling and marketing expenses in the six months ended June 30, 2009 compared to the same period of 2008 was primarily due to the following factors:

·	Promotional materials and fees increased 35.2% from $5,483,559 to $7,412,340 during the six months ended June 30, 2009 as compared to the same period of 2008. This was primarily due to the increase in our promotion activities and initiatives to support the continuous growth of our revenue.

·	Shipping increased 26.6% from $1,464,589 to $1,854,302 during the first two quarters of 2009 as compared to the same quarters of 2008. This was primarily due to the increase of net sales..

Advertising

Advertising expenses increased by $1,500,721 from $11,846,572 in the first two quarters of 2008 to $13,347,293 in the same quarters of 2009. The increase in advertising expense resulted from an increase in promotional efforts and media advertisement to promote the Company’s Jinji series, Boke Nose Spray and Protein Peptide series of products.

Advertising expenses as a percentage of revenue decreased slightly from 12.1% in the six months ended June 30, 2008 to 11.3% in the same period of 2009.

General and Administrative

General and administrative expenses decreased from $9,165,957 in the six months ended June 30 of 2008 to $8,881,357 in the same period of 2009, or a 3.1% decrease. The details of general and administrative expenses were as follows:

	Six Months Ended June 30,
	2009		2008			Increase/ (Decrease)			Increase/ (Decrease)
Payroll	$	1,597,265	$	1,865,961		$	(268,696	)		(14.4	)%
Directors’ remuneration		1,228,002		1,159,684			68,318			5.9	%
Professional fees – accounting		1,428,197		1,190,877			237,320			19.9	%
Research and development		631,996		488,413			143,583			29.4	%
Staff welfare and insurance		618,679		820,920			(202,241	)		(24.6	)%
Trip and traveling		496,382		530,767			(34,385	)		(6.5	)%
Office supplies		328,400		362,364			(33,964	)		(9.4	)%
Vehicles and utilities		267,625		281,504			(13,879	)		(4.9	)%
Provision for bad debts		276,371		(143,109	)		419,480			(293.1	)%
Stock compensation - Management and consult		248,463		104,500			143,963			137.8	%
Professional fees – legal and consulting		236,913		847,855			(610,942	)		(72.1	)%
Investors relation and listing expenses		145,234		146,065			(831	)		(0.6	)%
Office rental		49,882		112,402			(62,520	)		(55.6	)%
Other expenses		1,327,948		1,397,754			(69,806	)		(5.0	)%
TOTAL	$	8,881,357	$	9,165,957		$	(284,600	)		(3.1	)%

The increase in general and administrative expenses in the six months ended June 30, 2009 compared to the same period during 2008 was primarily due to the following factors:

·	Accounting related professional fees increased by $237,320, or 20% as compared to the same period of 2008, due primarily to the increase in audit fees relating to our increased number of subsidiaries being audited; and

Legal and consulting related professional fees decreased by $610,942, or 72.1% as compared to the same period during 2008. We incurred increased fees during the second quarter of 2008, due to fund raising activities undertaken during that time. We did not have any fund raising activities during the second quarter of 2009 ; and

·	Payroll expenses decreased by $268,696, or 14.4% and Staff welfare and insurance expenses decreased by $202,241, or 24.6% as compared to the same quarter during 2008. These reflect the Company’s increased efforts in optimization of human resource management and cost control; and

·	Research and development increased by $143,583, or 29.4%, as compared to the same period of 2008, due to our increased R&D effort on new products and existing products enhancement;

Depreciation and Amortization

Depreciation and amortization expenses increased by $1,721,518, or 86.6%, in the six months ended June 30, 2009 compared to the same period of 2008. This increase was primarily due to the depreciation and amortization charges of the facilities and lands acquired during 2008.

Depreciation and amortization expense for the R&D facilities was $398,720 for the six months ended June 30, 2009.

Interest Income (Expense), Net

Net interest expense was $3,199,338 for the six months ended June 30, 2009, compared to net interest expense of $13,769 for the six months ended June 30, 2008. The increase was mainly related to the convertible notes issued in July 2008.

Other expense, Net

Other expense was $114,938 for the six months ended June 30, 2009 compared to $356,502 for the six months ended June 30, 2008. Other expense in the second quarter of 2008 was primarily due to our donation of $168,641 related to the Sichuan earthquake relief during the second quarter of 2008. There were no such donations during the second quarter of 2009.

Income Taxes

Income tax expense for the six months ended June 30, 2009 was $5,472,406, compared to $6,361,562 for the six months ended June 30, 2008. The Company’s effective tax rate during the six months ended June 30, 2009 was 20.7%.

LIQUIDITY AND CAPITAL RESOURCES

Cash

Our cash balance at June 30, 2009 was $100,730,402, representing an increase of $30,093,892 or 42.6%, compared with our cash balance of $70,636,510 at December 31, 2008. The increase was mainly attributable to the net cash provided by operating activities of $26,540,242.

We plan to use our cash for acquisitions, research and development activities, sales and marketing of our products, and other general corporate purposes. We manage our cash based on thorough consideration of our corporate strategy as well as the macro economic situation. Factors we take into account when managing our cash include interest income, foreign currency fluctuation as well as the flexibility in executing our acquisition strategy.

Cash Flow

Cash flows from operations during the six months ended June 30, 2009 amounted to $26,540,242, representing a decrease of approximately 6.5% compared with cash flows from operations of $28,374,749 in the same period of 2008. The decreased cash flow was primarily due to the decrease in our net income by 9.9%, to $20,976,350 during the six months ended June 30, 2009, compared with net income of $23,281,820 in the same period last year. The decrease was also due to the increase in our inventories of $3,841,052 to support our increased purchase and production activities, the decrease in other payables and accrued expenses by $5,514,977. The decreased cash flow was offset by a decrease in our accounts receivable of $5,307,187.

Our cash flows provided by investing activities amounted to $4,420,524 during the six months ended June 30, 2009. During that period, we received $6,396,996 for refundable deposit for due diligence. We also paid 535,881 for the purchases of construction in progress during that period.

Our cash flows used in financing activities amounted to $984,430 during the six months ended June 30, 2009. During that period, we repaid $5,276,275 bank loans and received $4,817,870 from the short-term bank loans.

Working Capita l

Our working capital increased by $26,267,293 to $112,682,903 at June 30, 2009 as compared to $86,415,610 at December 31, 2008, primarily due to our increase in cash of $30,093,892, inventories of $3,787,711, a decrease of $5,514,979 in other payables and accrued expenses. The increase was partly offset by a decrease in accounts receivable of $5,585,286, refundable deposit of $6,396,996. The increase in inventory was mainly due to our maintaining higher inventory levels to prepare for increased operating activities.

We currently generate our cash flow through operations. We believe that our cash flow generated from operations will be sufficient to sustain operations for at least the next twelve months. From time to time, we may identify new expansion opportunities for which there will be a need to use cash.

As of June 30, 2009, the Company has $1,429,053 material unconditional purchase commitments for raw materials within one year and $0 after one year.

ISSUANCE OF COMMON STOCK

During the three months ended June 30, 2009, the Company issued 9,704 shares of restricted common stock as stock compensation in connection with the services rendered by a consultant.

INFLATION

Inflation has not had a material impact on our business and we do not expect inflation to have an impact on our business in the near future.

CURRENCY EXCHANGE FLUCTUATIONS

All of the Company’s revenues and a majority of its expenses in the three months ended June 30, 2009 were denominated in Renminbi (“RMB”), the currency of China, and were converted into US dollars at the exchange rate of 6.8448 to1. In the third quarter of 2005, the Renminbi began to rise against the US dollar. As a result of the appreciation of the RMB, we recognized a foreign currency translation gain of $424,782 during the six months ended June 30, 2009. There can be no assurance that RMB-to-U.S. dollar exchange rates will remain stable. A devaluation of RMB relative to the U.S. dollar would adversely affect our business, consolidated financial condition and results of operations. We do not engage in currency hedging.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not hold any derivative instruments and do not engage in any hedging activities. Because most of our purchases and sales are made in RMB, any exchange rate change affecting the value of the RMB relative to the U.S. dollar could have an effect on our financial results as reported in U.S. dollars. If the RMB were to depreciate against the U.S. dollar, amounts reported in U.S. dollars would be correspondingly reduced. If the RMB were to appreciate against the U.S. dollar, amounts reported in U.S. dollars would be correspondingly increased.

ITEM 4 – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report (the “Evaluation Date”), we carried out an evaluation in accordance with the requirements of auditing standards and applicable U.S. rules. The Company’s internal audit group, which includes its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with respect to this Quarterly Report on Form 10-Q before its filing with the Commission. The audit group made its evaluation pursuant to Rule 13a-15 under the Exchange Act.

Based upon our evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective. Given the fact that our major operations are located China, the Company and the internal audit group consistently make efforts to coordinate the evolving control and disclosure environment in China with the regulatory environment in the United States. The Company has identified this aspect as an area for improvement and is taking measures to train its staff for better performance.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the second quarter of 2009 covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of our executive officers or any of our subsidiaries, threatened against or affecting our company, our common stock, or any of our subsidiaries, or against our Company’s or our Company’s subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

ITEM 1A – RISK FACTORS

In our Annual Report on Form 10-K for the year ended December 31, 2008, we disclosed new risks and material changes from risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2007. There have been no material changes or new risks during the quarter ended June 30, 2009 to be disclosed. We hereby incorporate by reference the risk factors set forth in Item 1A of the Annual Report of Form 10-K for the year ended December 31, 2008.

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended June 30, 2009, the Company issued 9,704 shares of restricted common stock as stock compensation in connection with the services rendered by a consultant. The issuance of the foregoing shares was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

There have been no material defaults.

ITEM 4 – SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted to a vote of security holders during the period covered by this report.

ITEM 5 – OTHER INFORMATION

Not applicable.

ITEM 6 – EXHIBITS

The following exhibits are filed as part of this Quarterly Report on Form 10-Q:

Exhibit No.	Description
31.1	Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a – 14(a) of the Securities Exchange Act, as amended
31.2	Certification of Acting Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a – 14(a) of the Securities Exchange Act, as amended
32.1	Certification of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. 1350, as adopted.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMERICAN ORIENTAL BIOENGINEERING, INC.

/s/ Tony Liu

TONY LIU

CHAIRMAN AND CHIEF EXECUTIVE OFFICER

DATED: August 7, 2009

/s/ Yanchun Li

YANCHUN LI

CHIEF FINANCIAL OFFICER

DATED: August 7, 2009

EXHIBIT INDEX

Exhibit No.	Description
31.1	Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a – 14(a) of the Securities Exchange Act, as amended
31.2	Certification of Acting Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a – 14(a) of the Securities Exchange Act, as amended
32.1	Certification of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. 1350, as adopted.

American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more American Oriental Bioengineering, Inc. Charts.

American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AOB American Oriental Bioengineering, Inc.

News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AOB American Oriental Bioengineering, Inc.

News

Your Recent History

Company

Business

Popular

Get The App